Logo Prima Biomed

Welcome to the Newsroom

20 January 2017

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer




SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the
“Company”) today announced the first patient has been dosed as part of the enlarged
randomised phase of its AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer.